The Medicines Co.
www.themedicinescompany.com
Latest From The Medicines Co.
Potential Cardiovascular Blockbuster Inclisiran Among New Filings At EMA
The European Medicines Agency has agreed to review pan-EU marketing applications for a number of new medicines.
Novartis’s Inclisiran Unscathed As Arrowhead Falls Short
Arrowhead’s drug has failed to match inclisiran’s performance, but its RNAi platform has other promising candidates.
In Vivo's Rough Guide On The State Of RNAi
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. In Vivo reviews the leading drug developers in this space.
Keeping Track: Aimmune’s Peanut Allergen Approved; Novartis’ Inclisiran, Pfizer/Lilly’s Tanezumab, Bayer’s Nifurtimox Submitted
Highlights of the latest drug development news from our US FDA Performance Tracker.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Cardiovascular
- Infectious & Viral Diseases
- Inflammation
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- The Medicines Co.
- Senior Management
-
Mark Timney, CEO
Chris Visioli, CFO
Diane Sullivan, Chief Commercial Officer
Peter Wijngaard, PhD, Chief Dev. Officer - Contact Info
-
The Medicines Co.
Phone: (973) 290-6000
8 Sylvan Way
Parsippany, NJ 07054
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice